Farabi Pharmaceutical (XTEH:DFRB1) Asset Turnover: 0.00 (As of . 20)


What is Farabi Pharmaceutical Asset Turnover?

Farabi Pharmaceutical XTEH:DFRB1 Asset Turnover is 0.00 as of . 20.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Farabi Pharmaceutical's Revenue for the three months ended in . 20 was IRR Mil. Farabi Pharmaceutical's Total Assets for the quarter that ended in . 20 was IRR Mil. Therefore, Farabi Pharmaceutical's Asset Turnover for the quarter that ended in . 20 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Farabi Pharmaceutical's annualized ROE % for the quarter that ended in . 20 was %. It is also linked to ROA % through Du Pont Formula. Farabi Pharmaceutical's annualized ROA % for the quarter that ended in . 20 was %.


Farabi Pharmaceutical  (XTEH:DFRB1) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Farabi Pharmaceutical's annulized ROE % for the quarter that ended in . 20 is

ROE %**(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*(/ )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

Note: The Net Income data used here is four times the quarterly (. 20) net income data. The Revenue data used here is four times the quarterly (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Farabi Pharmaceutical's annulized ROA % for the quarter that ended in . 20 is

Note: The Net Income data used here is four times the quarterly (. 20) net income data. The Revenue data used here is four times the quarterly (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Farabi Pharmaceutical Asset Turnover Related Terms


Farabi Pharmaceutical Asset Turnover Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical Asset Turnover Chart

Farabi Pharmaceutical Annual Data
Trend
Asset Turnover

Farabi Pharmaceutical Quarterly Data
Asset Turnover

XTEH:DFRB1 vs IMNPQ, INNV: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farabi Pharmaceutical Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Farabi Pharmaceutical's Asset Turnover falls into.



Farabi Pharmaceutical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Farabi Pharmaceutical's Asset Turnover for the fiscal year that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
=

Farabi Pharmaceutical's Asset Turnover for the quarter that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Asset Turnover of 0.00 as of . 20. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Asset Turnover too high?
Farabi Pharmaceutical's current Asset Turnover is 0.00.
How does Farabi Pharmaceutical's Asset Turnover compare to IMNPQ and INNV?
Farabi Pharmaceutical's Asset Turnover of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Asset Turnover is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.